Unknown

Dataset Information

0

Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin.


ABSTRACT: CONTEXT:In the ODYSSEY CHOICE I trial, alirocumab 300 mg every 4 weeks (Q4W) was assessed in patients with hypercholesterolemia. Alirocumab efficacy and safety were evaluated in a patient subgroup with type 2 diabetes mellitus (T2DM) and who were receiving maximally tolerated statins with or without other lipid-lowering therapies. METHODS:Participants received either alirocumab 300 mg Q4W (n = 458, including 96 with T2DM) or placebo (n = 230, including 50 with T2DM) for 48 weeks, with alirocumab dose adjustment to 150 mg every 2 weeks at Week (W) 12 if W8 low-density lipoprotein cholesterol (LDL-C) levels were ?70 mg/dL or ? 100 mg/dL, depending on cardiovascular risk, or if LDL-C reduction was <30% from baseline. Efficacy end points included percentage change from baseline to W24 for lipids, and time-averaged LDL-C over W21 to W24. RESULTS:In individuals with T2DM, LDL-C reductions from baseline to W24 and the average of W21 to W24 were significantly greater with alirocumab (-61.6% and -68.8%, respectively) vs placebo. At W24, alirocumab significantly reduced levels of non-high-density lipoprotein cholesterol (HDL-C) and other lipids. At W24, 85.9% and 12.5% of individuals in the alirocumab and placebo groups, respectively, reached both non-HDL-C <100 mg/dL and LDL-C <70 mg/dL. At W12, In total, 18% of alirocumab-treated participants received dose adjustment. The most common treatment-emergent adverse events were upper respiratory tract infection and injection-site reaction. No clinically significant changes in fasting plasma glucose and glycated hemoglobin were observed. CONCLUSION:In individuals with T2DM, alirocumab 300 mg Q4W was generally well tolerated and efficacious in reducing atherogenic lipoproteins.

SUBMITTER: Muller-Wieland D 

PROVIDER: S-EPMC6763278 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin.

Müller-Wieland Dirk D   Rader Daniel J DJ   Moriarty Patrick M PM   Bergeron Jean J   Langslet Gisle G   Ray Kausik K KK   Manvelian Garen G   Thompson Desmond D   Bujas-Bobanovic Maja M   Roth Eli M EM  

The Journal of clinical endocrinology and metabolism 20191101 11


<h4>Context</h4>In the ODYSSEY CHOICE I trial, alirocumab 300 mg every 4 weeks (Q4W) was assessed in patients with hypercholesterolemia. Alirocumab efficacy and safety were evaluated in a patient subgroup with type 2 diabetes mellitus (T2DM) and who were receiving maximally tolerated statins with or without other lipid-lowering therapies.<h4>Methods</h4>Participants received either alirocumab 300 mg Q4W (n = 458, including 96 with T2DM) or placebo (n = 230, including 50 with T2DM) for 48 weeks,  ...[more]

Similar Datasets

| S-EPMC5079013 | biostudies-literature
| S-EPMC4430683 | biostudies-literature
| S-EPMC4190302 | biostudies-literature
| S-EPMC5055560 | biostudies-literature
| S-EPMC7153222 | biostudies-literature
| S-EPMC5984942 | biostudies-literature
| S-EPMC6175384 | biostudies-literature
| S-EPMC5240065 | biostudies-other
| S-EPMC5474052 | biostudies-literature
| S-EPMC5379546 | biostudies-literature